What do systematic reviews say?

Summary of findings ‐ computerised learning vs traditional learning

• E‐learning for health professionals 2018 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 3236 participants
  Low

Probiotics vs placebo or control

Summary of findings: Probiotics may leads to lower diarrhoea (grade 2+) compared with control (placebo or no intervention) (low certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 0.43 [0.22, 0.82]
  5 studies · 923 participants
  Low

Probiotics vs placebo or control

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Evening RT vs morning RT

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Evening RT vs morning RT

Summary of findings: Evening RT may leads to lower acute and late GI toxicity (grade 2+) compared with morning RT (low certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 0.51 [0.34, 0.76]
  2 studies · 294 participants
  Low

Summary of findings: Evening RT vs morning RT

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 participants
  GRADE not reported

Summary of findings: Evening RT vs morning RT

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sucralfate vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sucralfate vs placebo

Summary of findings: Sucralfate showed no clear difference in acute and late GI toxicity (grade 2+) [acute = during RT; late = 6… compared with placebo (moderate certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 1.07 [0.83, 1.39]
  1 study · 335 participants
  Moderate

Sucralfate vs placebo

Summary of findings: Sucralfate may leads to lower diarrhoea (grade 2+) [during RT] compared with placebo (low certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 0.81
  4 studies · 284 participants
  Low

Sucralfate vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Amifostine vs no intervention

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Amifostine vs no intervention

Summary of findings: Amifostine may leads to lower acute and late GI toxicity (grade 2+) compared with no intervention (low certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 0.25
  3 studies · 278 participants
  Low

Amifostine vs no intervention

It is very uncertain whether summary of findings: Amifostine changes diarrhoea (grade 2+) during treatment compared with no intervention (very low certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 0.25 [0.06, 0.98]
  1 study · 36 participants
  Very low

Amifostine vs no intervention

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Octreotide vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Octreotide vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Octreotide vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Octreotide vs placebo

Summary of findings: Octreotide showed no clear difference in diarrhoea (grade 2+) compared with placebo (moderate certainty).

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  RR 1.01 [0.76, 1.35]
  2 studies · 340 participants
  Moderate

Summary of findings: Octreotide vs placebo

The review found no eligible studies for this question.

• Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found